Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13361592 | 0.87 | GRIN1 (0.47) | SLC6A4SIGMAR1TMEM97GRIN1GRIN2A | |
| SCHEMBL26232267 | 0.87 | GRIN1 (0.47) | SLC6A4SIGMAR1TMEM97GRIN1GRIN2A | |
| SCHEMBL22803241 | 0.80 | OPRM1 (0.52) | SLC6A4SIGMAR1GRIN1GRIN2AGRIN2D | |
| SCHEMBL24224567 | 0.79 | SLC6A4 (0.40) | SLC6A4SIGMAR1TMEM97SLC6A3TDP1 | |
| SCHEMBL21670909 | 0.74 | SLC6A4 (0.51) | SLC6A4SIGMAR1TMEM97SLC6A3GRIN1 | |
| SCHEMBL18236060 | 0.73 | OPRD1 (0.47) | OPRM1OPRK1 | |
| SCHEMBL22945773 | 0.73 | GRIN1 (0.46) | SLC6A4SIGMAR1TMEM97SLC6A3GRIN1 | |
| SCHEMBL18460931 | 0.72 | GRIN1 (0.49) | SLC6A4SIGMAR1TMEM97GRIN1GRIN2A | |
| SCHEMBL24168724 | 0.72 | GRIN1 (0.41) | SLC6A4SIGMAR1TMEM97GRIN1GRIN2A | |
| SCHEMBL18458898 | 0.71 | DRD2 (0.37) | SLC6A4SIGMAR1TMEM97GRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285387-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20220023292-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285387-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | MAOB, DBH, OPRL1 | SLC6A4 14/4885SIGMAR1 26/4885TMEM97 693/4885 |
| US-20220023292-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | MAOB, DBH, OPRL1 | SLC6A4 14/4885SIGMAR1 26/4885TMEM97 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.